FDA Lifts Clinical Hold on Intellia’s MAGNITUDE Phase 3 Trial for ATTR-CM
Event summary
- FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 trial for nexiguran ziclumeran (nex-z) in ATTR-CM patients.
- The hold was imposed in October 2025 due to observed Grade 4 liver transaminases and increased total bilirubin in a patient.
- Mitigation measures include enhanced liver monitoring, short-term steroid treatment guidelines, and additional patient exclusion criteria.
- MAGNITUDE is a randomized, double-blind, placebo-controlled trial with approximately 1,200 patients.
The big picture
The FDA’s decision to lift the clinical hold on Intellia’s MAGNITUDE trial is a critical step forward for nex-z, a CRISPR-based therapy aiming to treat ATTR-CM. This development comes amid growing interest in gene editing technologies, which promise transformative, one-time treatments for genetic disorders. The resolution of regulatory hurdles will be closely watched, as it could set a precedent for other CRISPR-based therapies in development.
What we're watching
- Regulatory Compliance
- How Intellia’s enhanced safety measures will impact the pace of MAGNITUDE trial enrollment and completion.
- Clinical Efficacy
- Whether the mitigation strategies will prevent further safety issues and ensure the trial’s success.
- Market Positioning
- The potential for nex-z to become the first one-time treatment for ATTR-CM and ATTRv-PN, given the competitive landscape.
Related topics